- Home
- EAD vs LRMR Comparison
EAD vs LRMR Comparison
Compare EAD & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EAD | LRMR |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 385.3M | 455.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | EAD | LRMR |
|---|---|---|
| Price | $6.52 | $3.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 145.0K | ★ 1.8M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 8.91% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,816.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.24 | $1.80 |
| 52 Week High | $7.18 | $6.42 |
Technical Indicators
Market Signals| Indicator | EAD | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 45.22 | 35.07 |
| Support Level | $6.24 | $3.14 |
| Resistance Level | $6.73 | $3.78 |
| Average True Range (ATR) | 0.05 | 0.28 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 44.44 | 22.79 |
Price Performance
Historical ComparisonAbout EAD Allspring Income Opportunities Fund
Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.